Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 5, Issue 4, pp 221–226 | Cite as

Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate

  • Stephen B. Howell
  • Susan J. Mansfield
  • Raymond Taetle
Original Articles Methotrexate Toxicity

Summary

Thymidine (dThd) concentrations have been measured in the sera of normal subjects and solid tumor cancer patients by means of a sensitive high-pressure liquid chromatographic assay to determine whether natural and methotrexate (MTX)-induced fluctuations were large enough to alter the toxicity of MTX to marrow. The mean concentration in normal subjects with measurable levels was 1.3x10-7 M (range <4x10-8 to 6x10-7 M). In cancer patients it was 2.0x10-7 M (range <4x10-8 to 8.7x10-7), and in malignant effusions 1.2x10-7 M (range <4x10-8 to 2.2x10-7 M). The wide range of variation in random samples was also found when multiple samples were obtained from the same patient during a 24-h period where dThd concentration varied from a minimum of two- to greater than six-fold. Treatment with MTX 3 mg/m2 caused an average 59% reduction in serum dThd during the first 24 h after injection during nine courses of therapy. dThd was tested for its ability to modulate the toxicity of MTX to human granulocate colony-forming units in culture across the concentration range found in vivo: changes in dThd concentration equivalent to normal fluctuations in vivo altered colony survival by 31% to >72%. A reduction in culture dThd equivalent to that produced in vivo by high-dose TMX increased colony kill by 25%. The results indicate that in vivo variations in serum dThd are in an appropriate range and of a sufficient magnitude to alter the toxicity of MTX to marrow, and they demonstrate that MTX can modulate its own toxicity by reducing serum dThd.

Keywords

Methotrexate Thymidine Measurable Level Multiple Sample Tumor Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

The abbreviations used are

CFU-GM

granulocyte/macrophage colony-forming units

dThd

thymidine

5-FU

5-fluorouracil

FdUrd

fluorodeoxyuridine

HPLC

high-pressure liquid chromatography

MTX

methotrexate

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bjursell G, Reichard P (1973) Effects of thymidine on deoxyribonucleoside triphosphate pools and deoxyribonucleic acid synthesis in Chinese hamster ovary cells. J Biol Chem 248:3904–3909Google Scholar
  2. 2.
    Breitman TR, Keene BR (1979) Synergistic cytotoxicity to melanomas and leukemias in vitro with thymidine and arabinosylcytosine. Proc Am Assoc Cancer Res 20:89Google Scholar
  3. 3.
    Carrico CK, Glazer RK (1979) Augmentation by thymidine of the incorporation and distribution of 5-fluorouracil in ribosomal RNA. Biochem Biophys Res Commun 87:664–670Google Scholar
  4. 4.
    Case CE, Paterson ARP (1977) Inhibition of thymidine uptake in asynchronous HeLa cells by nitrobenyzlthioinosine. Exp Cell Res 105:427–435Google Scholar
  5. 5.
    Cooper RA, Perry S, Breitman TR (1966) Pyrimidine metabolism in human leukocytes. I. Contribution of exogenous thymidine to DNA-thymine and its effect on thymine nucleotide synthesis in leukemic leukocytes. Cancer Res 26:2267–2275Google Scholar
  6. 6.
    Ensminger WD, Frei E III (1977) The prevention of methotrexate toxicity by thymidine infusions in man. Cancer Res 37:1851–1863Google Scholar
  7. 7.
    Gallo RC, Perry S, Breitman JR (1967) The enzymatic mechanisms for deoxythymidine synthesis in human leukocytes. J Biol Chem 242:5059–5068Google Scholar
  8. 8.
    Grant S, Lehman C, Cadman E (1980) Enhancement of 1-β-d-arabinofuranosylcytosine accumulation within L1210 cells and increase cytotoxicity following thymidine exposure. Cancer Res 40:1525–1531Google Scholar
  9. 9.
    Hakala MT, Taylor E (1958) The ability of purine and thymine derivatives and of glycine to support the growth of mammalian cells in culture. J Biol Chem 234:126–128Google Scholar
  10. 10.
    Hansen HH, Selawry OS, Holland JF, McCall CB (1971) The variability of individual tolerance to methotrexate in cancer patients. Br J Cancer 25:298–305Google Scholar
  11. 11.
    Harris AW, Reynolds EC, Finch LR (1979) Effect of thymidine on the sensitivity of cultured mouse tumor cells to 1-β-d-arabinofuranosylcytosine. Cancer Res 39:538–541Google Scholar
  12. 12.
    Heidelberger C (1965) Fluorinated pyrimidines. Prog Nucleic Acid Res 4:1–50Google Scholar
  13. 13.
    Holden L, Hoffbrand AV, Tattersall MHN (1980) Thymidine concentrations in human sera: variations in patients with leukemia and megaloblastic anaemia. Eur J Cancer 16:115–121Google Scholar
  14. 14.
    Howell SB, Ensminger WD, Krishan A, Frei E III (1978) Thymidine rescue of high dose methotrexate in humans. Cancer Res 38:325–330Google Scholar
  15. 15.
    Howell SB, Krishan A, Frei E III (1979a) Cytokinetic comparison of thymidine and leucovorin rescue of marrow in humans after exposure to high-dose methotrexate. Cancer Res 39:1315–1320Google Scholar
  16. 16.
    Howell SB, Taetle R, Mendelsohn J (1979b) Thymidine as chemotherapeutic agent: sensitivity of normal human marrow, peripheral blood T cells, and acute non-lymphocytic leukemia. Blood 55:505–510Google Scholar
  17. 17.
    Howell SB, Herbst K, Boss GR, Frei E III (1980) Thymidine requirements for the rescue of patients treated with high dose methotrexate. Cancer Res 40:1824–1829Google Scholar
  18. 18.
    Jackson RC (1978) The regulation of thymidylate biosynthesis in Novikoff hepatoma cells and the effects of amethopterin, 5-fluoredeoxyuridine, and 3-deazauridine. J Biol Chem 253:7440–7446Google Scholar
  19. 19.
    Khym JX (1975) An analytical system for rapid separation of tissue nucleotides at low pressure on conventional anion exchangers. Clin Chem 21:1245–1252Google Scholar
  20. 20.
    Krstulovic AM, Brown PR, Rosie DM (1977) Identification of nucleosides and bases in serum and plasma samples by reverse-phase high performance liquid chromatography. Anal Chem 49:2237–2241Google Scholar
  21. 21.
    Martin DS, Stolfi RL, Spiegelman S (1978) Striking augmentation of the in vivo anticancer activity of 5-fluorouracil (FU) by combination with pyrimidine nucleosides. Proc Am Assoc Cancer Res 19:221Google Scholar
  22. 22.
    Pinedo HM, Zaharko DS, Bull JM, Chabner BA (1976) The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res 26:4418–4424Google Scholar
  23. 23.
    Plagemann PGW, Erbe J (1974) The deoxyribonucleoside transport systems of cultured Novikoff rat hepatoma cell. J Cell Physiol 83:337–344Google Scholar
  24. 24.
    Sawyer R, Xnayak R, Spiegelman S, Martin D (1979) Mechanism of action of 5-fluorouracil (FU) in the chemotherapy of the murine mammary tumor. Proc Am Assoc Cancer Res 20:263Google Scholar
  25. 25.
    Semon JH, Grindey GB (1978) Protentiation of the antitumor activity of methotrexate by concurrent infusion of thymidine. Cancer Res 9:2905–2911Google Scholar
  26. 26.
    Spies TD, Frommeyer W Jr, Vilter CF, English A (1946) Anti-anemic properties of thymine. Blood 1:185–188Google Scholar
  27. 27.
    Stadecker MJ, Calderon J, Karnovsky ML, Unanue ER (1977) Synthesis and release of thymidine by macrophages. J Immunol 119:1738–1743Google Scholar
  28. 28.
    Stokes A, Lacey RW (1978) Effect of thymidine on activity of trimethoprim and sulfamethoxazole. J Clin Pathol 31:165–171Google Scholar
  29. 29.
    Tattersall MHN, Brown B, Frei E III (1978) The reversal of methotrexate toxicity by thymidine with maintenance of antitumor effects. Nature 253:198–200Google Scholar
  30. 30.
    Taylor-Papadimitriou J, Rozengurt E (1979) The role of thymidine uptake in the control of cell proliferation. Exp Cell Res 119:393–396Google Scholar
  31. 31.
    Vogel SJ, Presant CA, Ratkin GA, Klahr C (1979) Phase I study of thymidine plus 5-fluorouracil infusions in advanced colorectal carcinoma. Cancer Treat Rep 63:1–5Google Scholar
  32. 32.
    Woodcock WM, Martin DS, Kemeny N, Young CW (1978) Phase I evaluation of thymidine plus fluorouracil (TdR+FU) in patients with advanced cancer. Proc Am Assoc Cancer Res 19:351Google Scholar

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • Stephen B. Howell
    • 1
    • 2
  • Susan J. Mansfield
    • 1
    • 2
  • Raymond Taetle
    • 1
    • 2
  1. 1.Department of MedicineUniversity of California, San DiegoLa Jolla, CaliforniaUSA
  2. 2.the Cancer CenterUniversity of California, San DiegoLa Jolla, CaliforniaUSA

Personalised recommendations